An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis (Q34435465)

2 August 2017

1 reference

title

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis (English)

1 reference

stem cell transplantation

2 August 2017

1 reference

1 reference

Sanchorawala V

1

1 reference

2 August 2017

Wright DG

2

1 reference

2 August 2017

Seldin DC

3

1 reference

2 August 2017

Dember LM

4

1 reference

2 August 2017

Finn K

5

1 reference

2 August 2017

Falk RH

6

1 reference

2 August 2017

Berk J

7

1 reference

2 August 2017

Quillen K

8

1 reference

2 August 2017

Skinner M

9

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Bone Marrow Transplantation

2 August 2017

1 reference

2 August 2017

28

1 reference

2 August 2017

637-642

1 reference

2 August 2017

7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703200

2 August 2017

0 references

cites work

The systemic amyloidoses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

7 January 2021

Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

7 January 2021

Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703200

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703200

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference